Indivior PLC Ordinary Shares
Yahoo Finance • 2 months ago
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a singl... Full story
Yahoo Finance • 2 months ago
Top 3 Health Care Stocks That May Explode This Month
Top 3 Health Care Stocks That May Explode This Month Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The most oversold stocks in the health care sector present an opportunity to buy in... Full story
Yahoo Finance • 3 months ago
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume o... Full story
Yahoo Finance • 6 months ago
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance
RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivi... Full story
Yahoo Finance • 9 months ago
Fresh blow for London market as drug maker joins exodus to New York
Packages of Suboxone Indivior, the British drug maker, is to ditch its primary listing on the London Stock Exchange for New York in the latest blow to the Square Mile. The company, which makes treatments for opioid addiction and schizoph... Full story
Yahoo Finance • 9 months ago
Indivior PLC (LON:INDV) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Indivior fair value estimate is UK£24.66 Indivior is estimated to be 44% undervalued based on current share price of UK£13.88 Analyst price target for INDV is US$23.95 which is 2.9%... Full story
